US2017165112A1PendingUtilityA1
Trans-sclera portal for delivery of therapeutic agents
Est. expiryMar 15, 2033(~6.6 yrs left)· nominal 20-yr term from priority
A61M 2210/0612A61K 9/0051A61K 31/5575A61F 9/0017A61K 47/34A61M 2039/0276A61K 31/4168A61F 2250/0067A61F 9/0008A61F 2210/0061A61F 2250/0068A61K 31/498A61K 31/5377A61K 31/573A61K 31/337A61K 35/28A61K 9/0048A61K 9/0004A61K 9/06A61K 47/32A61K 39/3955G02B 1/043
54
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
A portal through the sclera for delivery of an effective amount of therapeutic agent to the back of the eye.
Claims
exact text as granted — not AI-modified1 - 29 . (canceled)
30 . A method of treating a patient's eye, comprising:
surgically implanting in the eye a swell loadable polymeric ocular insert with a micron scale tab that extends through the sclera as an external mass transport channel; and placing a therapeutic agent in contact with the ocular insert to thereby load the insert with the agent.
31 . The method of claim 30 , wherein the placing the therapeutic agent comprises one of:
dropping onto the eye eyedrops containing the therapeutic agent; and applying to the eye an eye wash containing the therapeutic agent.
32 . The method of claim 30 , wherein the placing the therapeutic agent comprises placing an appliance impregnated with the agent adjacent to and in removable contact with the scela and the tab; and
transferring from the appliance to the interior of the eye through the tab the therapeutic agent impregnated in the appliance.
33 . The method of claim 32 , wherein the appliance comprises a lens body formed of a block copolymer that is phase nanophase-separated to form a periodic nanostructure of therapeutic agent-miscible domains interspersed among a hydrogel matrix, wherein the therapeutic agent is impregnated in the agent-miscible domains.
34 . The method of claim 32 , further comprising:
removing the appliance from contact with the eye; placing a second time an appliance adjacent to and in removable contact with the sclera and the tab; and transferring from the second placed appliance to the interior of the eye through the tab a therapeutic agent impregnated in the appliance.
35 . The method of claim 32 , further comprising:
removing the appliance from contact with the eye; re-impregnating the appliance with a therapeutic agent; and replacing the re-impregnated appliance adjacent to and in removable contact with the sclera and the tab.
36 . A drug-delivering contact lens system for placement in an eye, comprising:
a removable lens body comprising therapeutic receiving domains; a therapeutic agent impregnated into the therapeutic agent receiving domains; a transport device implantable in the eye and capable of absorbing the therapeutic agent in a presence of the removable lens body external to the eye, and capable of delivering the therapeutic agent to an interior portion of the eye.
37 . The system of claim 36 , wherein the removable lens body is removed after substantial absorbing of the therapeutic agent by the transport device.
38 . The system of claim 36 , wherein the receiving domains are too small to scatter visible light.
39 . The system of claim 36 , wherein the receiving domains comprise a hydrogel matrix.
40 . The system of claim 39 , wherein the hydrogel matrix comprises HEMA or a silicone material.
41 . The system of claim 39 , wherein the receiving domains are more hydrophobic than the hydrogel matrix.
42 . The system of claim 36 , wherein the lens body is formed of one of PEA, a polymer made through metathesis polymerization, and a polymer made by controlled free radical polymerization.
43 . The system of claim 36 , wherein the lens body is reloadable with a fresh aqueous solution containing the therapeutic agent.
44 . The system of claim 43 , wherein the transport device is correspondingly reloaded with the fresh aqueous solution containing the therapeutic agent.
45 . The system of claim 36 , wherein the transport device is implantable through the sclera of the eye.
46 . The system of claim 36 , wherein the removable lens body is configured to be placed on the cornea of the eye.Join the waitlist — get patent alerts
Track US2017165112A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.